Last reviewed · How we verify
LEO 39652 cream
At a glance
| Generic name | LEO 39652 cream |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream (PHASE1)
- Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 39652 cream CI brief — competitive landscape report
- LEO 39652 cream updates RSS · CI watch RSS
- LEO Pharma portfolio CI